Hepatocellular carcinoma (hcc) Trials in Guangzhou, China
Conditions / Hepatocellular carcinoma (hcc) / Guangzhou, China
Hepatocellular carcinoma (hcc) has been the subject of sustained clinical investigation across multiple research sites.
27 total trials for this combination
Showing top 10 of 27 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | TERMINATED | PHASE3 |
| NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | RECRUITING | — |
| NCT07327034 | ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | RECRUITING | PHASE2 |
| NCT06487559 | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) | RECRUITING | PHASE1 |
| NCT02562755 | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone | COMPLETED | PHASE3 |
| NCT03412773 | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | COMPLETED | PHASE3 |
| NCT07170345 | Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion | RECRUITING | — |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | COMPLETED | PHASE3 |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | COMPLETED | PHASE1 |
| NCT03419897 | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | COMPLETED | PHASE2 |